The focus usually starts with reducing meal-time insulin dosing, and as you lose weight, you will likely need to reduce your basal doses as well
Other benefits of MOTS-c MOTS-cs diverse therapeutic effects may help users realize numerous downstream health effects: Diabetes: Inefficient glucose uptake is a characteristic of type 2 diabetes, and mitochondrial dysfunction may result in two risk factors for the disease insulin resistance and impaired insulin secretion.32 33 MOTS-cs actions on these risk factors may help nip them in the bud.34 Cardiovascular health: Diabetes is a cardiovascular risk factor, so cutting it from the picture can spell significant improvements in heart health.35 A high body-fat percentage is another such risk factor, so if MOTS-c can prevent obesity, it can halt the onset of a health condition characteristic of more than 80% of people with coronary heart disease.36 37 Longevity: Given the link between inflammation, age, and high-risk age-related diseases (e.g., atherosclerosis, cardiovascular disease), MOTS-c may increase lifespan as a continual downstream effect.38 Cognitive function: A 2022 review published in Progress in Neurobiology noted that metabolic modulators (which MOTS-c is) and exercise (which MOTS-c simulates) can be used in neuroprotective strategies.39 Or at least that has been the case in preclinical studies
78 SkoutaR.DixonS
This work is licensed under the Creative Commons Attribution-NonCommercial International License (CC BY-NC 4.0)
Pancreatic lipases cleave the butyrate molecules progressively through the intestine and into the colon delivering butyrate precisely where colonocytes need it.*
A pre-specified meta-analysis including all the seven clinical trials that constituted the clinical development program of tirzepatide (SURPASS) demonstrated its CV safety in patients with T2DM in terms of not increasing the risk of major adverse CV events (MACE)
